Saniona ABCHIX:SANIOS 65 3-Year RORE % is 110.64 as of Mar. 2026. GuruFocus rates CHIX:SANIOS with a GF Score™ of 65/100 and a GF Value™ of kr26.65 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,291 Biotechnology companies, Saniona AB ranks better than 96.44% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Saniona AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was 110.64%.
The industry rank for Saniona AB's 3-Year RORE % or its related term are showing as below:
CHIX:SANIOs's 3-Year RORE % is ranked better than 96.44% of 1291
companies
in the Biotechnology industry
Industry Median: -11.44
vs CHIX:SANIOs: 110.64
Saniona AB (CHIX:SANIOs) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Saniona AB 3-Year RORE % Related Terms
Saniona AB 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Saniona AB's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SANIOS vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Saniona AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Saniona AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Saniona AB (CHIX:SANIOS) has a 3-Year RORE % of 110.64 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Saniona AB and its competitors. According to the industry distribution chart, Saniona AB ranks #46 out of 1291 companies in the Biotechnology industry, placing it in the top 3.6%.
Is Saniona AB's 3-Year RORE % too high?
Saniona AB's current 3-Year RORE % is 110.64. Based on the distribution chart, Saniona AB ranks #46 out of 1291 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Saniona AB has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #46 out of 1291 companies for 3-Year RORE %. This places Saniona AB in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Saniona AB and its competitors. Saniona AB's current 3-Year RORE % is 110.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (CHIX:SANIOS) is currently considered Significantly Undervalued. The stock's GF Value™ is kr26.65, compared to a current price of kr12.75 — trading 52.2% below its estimated fair value. The current 3-Year RORE % is 110.64. Saniona AB's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Saniona AB (CHIX:SANIOS), the current 3-Year RORE % is 110.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (CHIX:SANIOS) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of kr12.75 is trading 52.2% below its estimated GF Value™ of kr26.65.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for CHIX:SANIOS:
3-Year RORE %: 110.64
GF Value™: kr26.65 vs. price of kr12.75 (52.2% below fair value)
No single metric tells the full story. See the CHIX:SANIOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
65GF Score
Get the complete analysis for CHIX:SANIOS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SANIOS has been successfully added to your 
